A low-frequency variant at 8q24.21 is strongly associated with risk of oligodendroglial tumors and astrocytomas with IDH1 or IDH2 mutation

Nature Genetics

Volumn 44, Issue 10, 2012, Pages 1122-1125

  Jenkins, Robert B ^a   Xiao, Yuanyuan ^b   Sicotte, Hugues ^a   Decker, Paul A ^a   Kollmeyer, Thomas M ^a   Hansen, Helen M ^b   Kosel, Matthew L ^a   Zheng, Shichun ^b   Walsh, Kyle M ^b,c   Rice, Terri ^b   Bracci, Paige ^b   McCoy, Lucie S ^b   Smirnov, Ivan ^b   Patoka, Joseph S ^b   Hsuang, George ^b   Wiemels, Joe L ^b,d   Tihan, Tarik ^b   Pico, Alexander R ^e   Prados, Michael D ^b   Chang, Susan M ^b   Berger, Mitchel S ^b   Caron, Alissa A ^a   Fink, Stephanie R ^a   Halder, Chandralekha ^a   Rynearson, Amanda L ^a   Fridley, Brooke L ^a   Buckner, Jan C ^a   O'Neill, Brian P ^a   Giannini, Caterina ^a   Lachance, Daniel H ^a   Wiencke, John K ^b,d   Eckel Passow, Jeanette E ^a   Wrensch, Margaret R ^b,d   more..

^a Mayo Clinic   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e GLADSTONE INSTITUTES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; MICRORNA;

ARTICLE; ASTROCYTOMA; CASE CONTROL STUDY; CHROMOSOME 19Q; CHROMOSOME 8Q; CHROMOSOME DELETION; CONTROLLED STUDY; GENE; GENE FREQUENCY; GENE MUTATION; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC CONSERVATION; GENETIC RISK; GENOTYPE; GLIOBLASTOMA; HISTOLOGY; HUMAN; HUMAN TISSUE; IDH1 GENE; IDH2 GENE; MODEL; OLIGODENDROGLIOMA; PRIORITY JOURNAL; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; WILD TYPE;

ADULT; AGED; ASTROCYTOMA; CASE-CONTROL STUDIES; CHROMOSOMES, HUMAN, PAIR 8; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; ISOCITRATE DEHYDROGENASE; MALE; MIDDLE AGED; OLIGODENDROGLIOMA; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; SEQUENCE ANALYSIS, DNA;

EID: 84866932650     PISSN: 10614036     EISSN: 15461718     Source Type: Journal    
DOI: 10.1038/ng.2388     Document Type: Article

References (35)

1. Shete, S. et al. Genome-wide association study identifies five susceptibility loci for glioma. Nat. Genet. 41, 899-904 (2009).
2. Jenkins, R.B. et al. Distinct germ line polymorphisms underlie glioma morphologic heterogeneity. Cancer Genet. 204, 13-18 (2011).
3. Sanson, M. et al. Chromosome 7p11.2 (EGFR) variation influences glioma risk. Hum. Mol. Genet. 20, 2897-2904 (2011).
4. Rice, T. et al. Associations of glioma risk loci by IDH1 mutation status. Neuro-oncol. 13 (suppl. 3), iii27 (2011).
5. Yan, H. et al. IDH1 and IDH2 mutations in gliomas. N. Engl. J. Med. 360, 765-773 (2009).
6. Christensen, B.C. et al. DNA methylation, isocitrate dehydrogenase mutation, and survival in glioma. J. Natl. Cancer Inst. 103, 143-153 (2011).
7. Houillier, C. et al. IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas. Neurology 75, 1560-1566 (2010).
8. van den Bent, M.J. et al. IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors, a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Clin. Cancer Res. 16, 1597-1604 (2010).
9. Hartmann, C. et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age, a study of 1,010 diffuse gliomas. Acta Neuropathol. 118, 469-474 (2009).
10. Cairncross, G. et al. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma, Intergroup Radiation Therapy Oncology Group Trial 9402. J. Clin. Oncol. 24, 2707-2714 (2006).
11. Idbaih, A. et al. Genomic aberrations associated with outcome in anaplastic oligodendroglial tumors treated within the EORTC phase III trial 26951. J. Neurooncol. 103, 221-230 (2011).
12. Teerlink, C. et al. A unique genome-wide association analysis in extended Utah high-risk pedigrees identifies a novel melanoma risk variant on chromosome arm 10q. Hum. Genet. 131, 77-85 (2012).
13. Sato, Y. et al. Genome-wide association study on overall survival of advanced non-small cell lung cancer patients treated with carboplatin and paclitaxel. J. Thorac. Oncol. 6, 132-138 (2011).
14. Low, S.K. et al. Genome-wide association study of pancreatic cancer in Japanese population. PLoS ONE 5, e11824 (2010).
15. Treviño, L.R. et al. Germline genomic variants associated with childhood acute lymphoblastic leukemia. Nat. Genet. 41, 1001-1005 (2009).
16. Mu, W. & Zhang, W. Bioinformatic resources of microRNA sequences, gene targets, and genetic variation. Front. Genet. 3, 31 (2012).
17. Stevens, K.N. et al. 19p13.1 is a triple negative-specific breast cancer susceptibility locus. Cancer Res. 72, 1795-1803 (2012).
18. Truong, T. et al. Replication of lung cancer susceptibility loci at chromosomes 15q25, 5p15, and 6p21: a pooled analysis from the International Lung Cancer Consortium. J. Natl. Cancer Inst. 102, 959-971 (2010).
19. Goode, E.L. et al. A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. Nat. Genet. 42, 874-879 (2010).
20. Gayther, S.A. & Pharoah, P.D. The inherited genetics of ovarian and endometrial cancer. Curr. Opin. Genet. Dev. 20, 231-238 (2010).
21. Al Olama, A.A. et al. Multiple loci on 8q24 associated with prostate cancer susceptibility. Nat. Genet. 41, 1058-1060 (2009).
22. Gudmundsson, J. et al. Genome-wide association and replication studies identify four variants associated with prostate cancer susceptibility. Nat. Genet. 41, 1122-1126 (2009).
23. Ghoussaini, M. et al. Multiple loci with different cancer specificities within the 8q24 gene desert. J. Natl. Cancer Inst. 100, 962-966 (2008).
24. Wang, K. et al. Interpretation of association signals and identification of causal variants from genome-wide association studies. Am. J. Hum. Genet. 86, 730-742 (2010).
25. Noushmehr, H. et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 17, 510-522 (2010).
26. Lu, C. et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature 483, 474-478 (2012).
27. Turcan, S. et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature 483, 479-483 (2012).
28. Wrensch, M. et al. Variants in the CDKN2B and RTEL1 regions are associated with high-grade glioma susceptibility. Nat. Genet. 41, 905-908 (2009).
29. Felini, M.J. et al. Reproductive factors and hormone use and risk of adult gliomas. Cancer Causes Control 20, 87-96 (2009).
30. Wrensch, M. et al. Nonsynonymous coding single-nucleotide polymorphisms spanning the genome in relation to glioblastoma survival and age at diagnosis. Clin. Cancer Res. 13, 197-205 (2007).
31. Smith, J.S. et al. Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J. Clin. Oncol. 18, 636-645 (2000).
32. Li, Y., Willer, C., Sanna, S. & Abecasis, G. Genotype imputation. Annu. Rev. Genomics Hum. Genet. 10, 387-406 (2009).
33. Purcell, S. et al. PLINK: a toolset for whole-genome association and population-based linkage analysis. Am. J. Hum. Genet. 81, 559-575 (2007).
34. Browning, B.L. & Browning, S.R. A unified approach to genotype imputation and haplotype-phase inference for large data sets of trios and unrelated individuals. Am. J. Hum. Genet. 84, 210-223 (2009).
35. Ding, Y., Chan, C.Y. & Lawrence, C.E. RNA secondary structure prediction by centroids in a Boltzmann weighted ensemble. RNA 11, 1157-1166 (2005).